Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

References for PMC Articles for PubMed (Select 19922614)

1.

Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ.

Dunne C, Burke JP, Morrow M, Kell MR.

J Clin Oncol. 2009 Apr 1;27(10):1615-20. doi: 10.1200/JCO.2008.17.5182. Epub 2009 Mar 2.

2.

Breast cancer. Clinical practice guidelines in oncology.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel.

J Natl Compr Canc Netw. 2009 Feb;7(2):122-92. Review. No abstract available.

PMID:
19200416
3.

Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.

Yen TW, Kuerer HM, Ottesen RA, Rouse L, Niland JC, Edge SB, Theriault RL, Weeks JC.

J Clin Oncol. 2007 Aug 1;25(22):3251-8. Epub 2007 Jun 18.

4.

SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening.

Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A; Swedish Breast Cancer Group.

Acta Oncol. 2006;45(5):536-43.

PMID:
16864166
5.

Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ.

J Clin Oncol. 2006 Jul 20;24(21):3381-7. Epub 2006 Jun 26.

6.
7.
8.

Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001.

Li CI, Daling JR, Malone KE.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1008-11.

9.

Trends in the treatment of ductal carcinoma in situ of the breast.

Baxter NN, Virnig BA, Durham SB, Tuttle TM.

J Natl Cancer Inst. 2004 Mar 17;96(6):443-8.

10.

Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.

Kerlikowske K, Molinaro A, Cha I, Ljung BM, Ernster VL, Stewart K, Chew K, Moore DH 2nd, Waldman F.

J Natl Cancer Inst. 2003 Nov 19;95(22):1692-702.

11.

Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.

Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M; UK Coordinating Committee on Cancer Research; Ductal Carcinoma in situ Working Party; DCIS trialists in the UK, Australia, and New Zealand.

Lancet. 2003 Jul 12;362(9378):95-102.

PMID:
12867108
12.

Detection of ductal carcinoma in situ in women undergoing screening mammography.

Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH, Urban N, Geller BM.

J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54.

13.

Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS.

Bijker N, Peterse JL, Fentiman IS, Julien JP, Hart AA, Avril A, Cataliotti L, Rutgers EJ.

Br J Cancer. 2002 Sep 9;87(6):615-20.

14.

Ductal carcinoma-in-situ.

Wickerham DL.

J Clin Oncol. 2001 Sep 15;19(18 Suppl):98S-100S. Review. No abstract available.

PMID:
11560982
15.
16.

Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ.

J Clin Oncol. 2001 Apr 15;19(8):2263-71.

PMID:
11304780
17.

Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sylvester R, Mignolet F, Bartelink H, Van Dongen JA.

Lancet. 2000 Feb 12;355(9203):528-33.

PMID:
10683002
18.

Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999.

Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI.

Cancer. 2000 Feb 15;88(4):946-54. Review. No abstract available.

PMID:
10679665
19.

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma.

Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N.

Cancer. 1999 Aug 1;86(3):429-38.

PMID:
10430251
20.

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH.

Lancet. 1999 Jun 12;353(9169):1993-2000.

PMID:
10376613
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk